Brain and Blood Biomarkers of Major Depressive Disorder: A Systematic Review - PubMed
4 hours ago
- #Biomarkers
- #Omics
- #Major Depressive Disorder
- Major depressive disorder (MDD) is a debilitating neuropsychiatric disease with high suicide risk.
- MDD is heterogeneous and polygenic, involving thousands of small-effect variants and significant epigenetic components.
- No biomarkers or precision-medicine treatments currently exist for MDD.
- Brain methylome and gene expression profiles may help identify biomarkers and treatment targets.
- A systematic review integrated findings from bulk and single-nuclei omics studies in MDD brain and blood.
- 744 differentially expressed genes and 544 differentially methylated genes were altered in both brain and blood.
- Several hub genes converged on developmental, inflammatory, transcriptional, apoptotic, and mitochondrial pathways.
- Converging pathways include neurodevelopment, mitochondria, neuroinflammation, apoptosis, and transcriptional regulation.
- Cell-type specific multiomic studies are needed to better understand MDD pathophysiology and identify biomarkers.